Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial.
Xiaorong ChenWeibing LengYuWen ZhouYongyang YuWenjian MengPeng CaoZiqiang WangMeng QiuPublished in: BMJ open (2023)
NCT05018182.
Keyphrases
- locally advanced
- open label
- rectal cancer
- phase ii study
- squamous cell carcinoma
- neoadjuvant chemotherapy
- clinical trial
- radiation therapy
- acute lymphoblastic leukemia
- acute myeloid leukemia
- phase ii
- lymph node
- study protocol
- phase iii
- randomized controlled trial
- hodgkin lymphoma
- combination therapy
- metastatic colorectal cancer
- smoking cessation